ArticleBMC gastroenterology2025
Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn's disease who develop secondary loss of response to infliximab.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFor patients with Crohn's disease (CD) who develop secondary loss of response (SLR) to infliximab (IFX), it remains unclear whether IFX optimization or direct conversion to ustekinumab (UST) offers better outcomes. This study aimed to identify risk factors for IFX optimization failure and to compare the clinical efficacy of IFX optimization versus UST conversion.
methodsWe retrospectively analyzed clinical data from patients with CD admitted to the First Affiliated Hospital of Wannan Medical College and the First Affiliated Hospital of the University of Science and Technology of China between January 2017 and January 2025. Rates of clinical, steroid-free, and endoscopic remission were assessed. Univariate and multivariate analyses were performed to identify independent risk factors for IFX optimization failure.
resultsIn total, 65 patients with CD who developed SLR to IFX were included. The patients were divided into three groups: IFX optimization success (Group 1), IFX optimization failure followed by UST (Group 2), and direct UST conversion (Group 3). Of the 28 patients who received IFX optimization, only 6 achieved success, yielding a failure rate of 78.6%. Multivariate logistic regression showed that a baseline albumin concentration of < 40 g/L was an independent predictor of IFX optimization failure (p = 0.047, odds ratio: 15.00, 95% confidence interval: 1.031-218.300). When comparing UST-treated groups, the rate of clinical response at week 6 was significantly higher in Group 3 than in Group 2 (35.1% vs. 9.1%, p = 0.039). By week 52, clinical remission rates were similar (86.4% vs. 89.2%, p > 0.05).
conclusionsGiven the high failure rate of IFX optimization, direct conversion to UST may provide greater benefit and reduce treatment costs in patients with CD who develop SLR to IFX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.